Related Experiment Videos
[Two patients with retroperitoneal paragangliomas]
J A Wegdam1, C S Andeweg, Q H Leyten
1Afd. Chirurgie, Rijnstate Ziekenhuis, Postbus 9555, 6800 TA Arnhem.
Nederlands Tijdschrift Voor Geneeskunde
|November 7, 2001
Summary
Paragangliomas are rare neuroendocrine tumors. Radical surgical excision is the primary treatment, but predicting malignancy and prognosis remains challenging, especially with metastatic disease.
Area of Science:
- Oncology
- Endocrinology
- Surgical Pathology
Background:
- Paragangliomas are rare neuroendocrine tumors arising from autonomic nervous system ganglia.
- These tumors, often presenting with abdominal complaints, are known by various names, leading to under-recognition.
- They can be functional, producing catecholamines, or non-functional.
Observation:
- A case series involving a 35-year-old woman and a 36-year-old man with retroperitoneal paragangliomas.
- The female patient experienced no recurrence after radical excision, while the male patient developed metastatic disease but survived for 6 years post-excision.
Findings:
- Currently, no definitive parameters predict benign versus malignant paraganglioma behavior in the absence of metastases.
- Macroscopic radical surgical excision is the recommended treatment of choice.
- Five- and ten-year survival rates after radical excision are 75% and 45%, respectively; metastatic disease carries a poor prognosis with 50% mortality within 3 years.
Implications:
- Genetic screening for familial neoplastic syndromes is advised upon paraganglioma diagnosis.
- Improved diagnostic criteria and understanding of prognostic factors are needed for better patient management.
- Further research into predicting malignancy and developing targeted therapies for metastatic paragangliomas is warranted.